Changes in menstrual bleeding are the most common and most consequential adverse effect of the etonogestrel implant. Headache, weight change, acne, breast pain and mood symptoms follow, but they rarely drive removal on their own. Counseling about Nexplanon side effects works best when it leads with bleeding, sets expectations for the first six to twelve months, and names the small number of findings that need same-day review.
Why it matters: Patients who know an unpredictable bleeding pattern is expected are far less likely to request early removal.
The Short Version
- Bleeding is the headline: pattern change is the most frequently reported effect and the leading reason for discontinuation.
- Timing is predictable in shape: local soreness within days, systemic symptoms within weeks, bleeding pattern settling over three to six months.
- Most systemic effects are modest: headache, acne, weight increase and breast pain were each reported by a minority of trial participants.
- Insertion and removal carry their own risks: deep placement, neurovascular injury and nonpalpable implants require imaging and referral, never blind exploration.
- New symptoms late in the term deserve a workup, not automatic attribution to the implant.
Bleeding Changes Dominate the Side Effect Profile
Irregular bleeding is the main reason patients ask for the implant to come out. In clinical studies summarized in the US prescribing information, roughly one in ten participants stopped using the implant because of an unfavorable bleeding pattern. Across 90-day reference periods, about one in five reported amenorrhea (no bleeding), around a third reported infrequent bleeding, and a smaller but clinically important minority reported frequent or prolonged bleeding.
There is no validated way to predict an individual’s pattern before insertion. The pattern seen in the first three months is loosely indicative of what follows, but it can shift at any point during use. That nuance belongs in the consent conversation: patients should hear that lighter or absent periods are common, that spotting may persist, and that neither outcome signals the implant is failing.
Management is supportive. US Selected Practice Recommendations describe options such as nonsteroidal anti-inflammatory drugs or, where medically appropriate and not contraindicated, a short course of hormonal therapy for bothersome bleeding; practical guidance is maintained by the CDC’s contraception practice recommendations for clinicians. Before attributing bleeding to the device, exclude pregnancy, sexually transmitted infection, cervical pathology and, where indicated, endometrial causes. Our clinical review of irregular bleeding after two years covers that workup in more detail.
Non-Bleeding Effects and How Often They Were Reported
Most other reactions are mild and self-limited. The table below summarizes approximate rates reported among participants in the clinical trial program, as described in the US prescribing information for the etonogestrel implant. Rates come from uncontrolled studies, so background incidence cannot be separated out.
| Reported effect | Approximate frequency in trials | Counseling note |
|---|---|---|
| Headache | About 1 in 4 | Usually mild; reassess if new, severe or focal |
| Vaginitis | About 1 in 7 | Evaluate discharge rather than assume hormonal cause |
| Weight increase | About 1 in 7 | No control group; causality not established |
| Acne | About 1 in 7 | Can improve or worsen; treat conventionally |
| Breast pain | About 1 in 8 | Often settles after the first months |
| Abdominal pain | About 1 in 9 | Exclude pregnancy, including ectopic, if new |
| Mood change or depressed mood | Under 1 in 10 | Label advises evaluation; consider removal if significant |
Weight is the question patients raise most often after bleeding. The honest answer is that weight increase was reported during use, but trials lacked a comparison arm, and progestin-only implants have not been shown to cause large or predictable gains. Mood symptoms deserve the same care: the label advises evaluating patients who develop significant depressive symptoms, and discontinuation is reasonable when symptoms are new, persistent and temporally linked. For background on the device itself, see our overview of the etonogestrel implant in contraceptive care.
When Do Nexplanon Side Effects Start, and How Do They Change by Year?
Local effects start immediately. Bruising, tenderness and mild swelling at the insertion site are expected for several days. Systemic symptoms such as headache, breast tenderness or acne typically appear within the first weeks. The bleeding pattern is the slowest to declare itself and usually stabilizes between three and six months.
Year one
Expect the most reporting here. Spotting is frequent, cycles are unpredictable, and discontinuation requests peak. Most non-bleeding complaints either resolve or become tolerable within this window.
Years two and three
Symptom burden usually falls, and many patients settle into infrequent bleeding or amenorrhea. A genuinely new symptom at this stage, such as heavy bleeding after a long quiet period, pelvic pain or a change in headache character, should prompt assessment rather than reassurance. Patients also ask whether returning periods mean the implant is wearing off; it generally does not, as covered in our note on what the signs of a declining implant actually indicate.
On duration, be precise. The approved length of use in the United States is defined by the current FDA-approved prescribing information, which clinicians should check directly before answering questions about three versus five years. Published studies have reported continued contraceptive effect beyond three years, but use past the approved duration stated on the current US label is off-label and should be framed that way. Current labeling can be verified through the FDA’s Drugs@FDA labeling database.
Who Should Not Receive the Implant
Contraindications in the US label include known or suspected pregnancy, current or prior thrombosis or thromboembolic disorders, liver tumors or active liver disease, undiagnosed abnormal genital bleeding, known or suspected breast cancer or other progestin-sensitive cancer, and hypersensitivity to any component. Undiagnosed bleeding is the one most often missed in a busy clinic; evaluate first, insert second.
Eligibility in more complicated cases is easier to settle with a reference. The US Medical Eligibility Criteria for Contraceptive Use grades conditions such as current breast cancer, severe liver disease and ischemic heart disease, and is the practical tool for borderline histories.
Drug interactions matter for efficacy, not just tolerability. Strong CYP3A4 inducers, including certain anticonvulsants, rifampin and St John’s wort, can lower etonogestrel concentrations and may reduce contraceptive effect; the label advises a backup method or an alternative contraceptive during and after such therapy. Serum levels are also inversely related to body weight, and the label notes limited data at higher body weights.
Insertion and Removal Complications: Recognition and Escalation
These are procedural risks, and the US label carries a specific warning about complications of insertion and removal. The recognized problems are failed insertion, placement that is too deep or in the wrong tissue plane, neural or vascular injury, and rare migration of the implant, including reports of movement into the pulmonary vasculature. Correct subdermal placement in the inner upper arm, away from the sulcus between biceps and triceps and well proximal to the medial epicondyle, is the primary safeguard.
Escalate, do not improvise. If the implant is not palpable after insertion or at removal, the patient should use another contraceptive method until it is located. Localize with high-frequency ultrasound or MRI; the implant is radiopaque and can also be seen on X-ray or CT. Measuring an etonogestrel level can confirm presence when imaging is inconclusive. Deep or nonpalpable implants should be removed by a clinician experienced with that scenario, often with imaging guidance, and never through blind exploratory dissection.
Patient-facing red flags are short and specific: spreading redness, discharge or fever at the site; an expanding hematoma; new numbness, tingling or weakness in the hand or arm; severe or persistent arm pain; and any chest pain or shortness of breath. Severe abdominal pain or a positive pregnancy test during use warrants prompt evaluation for ectopic pregnancy. Clinics refreshing their procedural standards can browse our injection safety article collection.
After Removal: What Changes and How Fast
Return of fertility is rapid. Etonogestrel concentrations fall quickly once the implant is out and are typically below assay sensitivity within about a week, so ovulation can resume within days. Patients who do not want pregnancy need a method in place at the removal visit, not afterward.
Questions about Nexplanon side effects after removal usually concern bleeding and mood. Most patients return to their pre-implant bleeding pattern within a few cycles, and a short period of irregularity in between is common. There is no established post-removal syndrome in the published literature, and symptoms that persist for months should be investigated on their own merits rather than attributed to the device. Expect site bruising and tenderness for several days, and document the removal site and condition of the retrieved implant.
When Side Effects Persist: Comparing the Alternatives
If bleeding or mood symptoms remain unacceptable after a fair trial, the conversation shifts to method fit rather than tolerance. Three factors usually decide it: how much bleeding predictability the patient wants, whether a systemic progestin is the problem, and how much procedural burden is acceptable. A levonorgestrel intrauterine system often reduces bleeding volume with lower systemic exposure, while an injectable progestin keeps dosing clinic-controlled but has its own profile. Our reviews of levonorgestrel IUS hormone effects and safety and long-term injectable progestin use set out those trade-offs for counseling.
Stock, Documentation and Procurement Notes
Handling is straightforward but unforgiving of shortcuts. Keep each implant sealed in its sterile preloaded applicator until the moment of use, follow the package insert for storage conditions, and check the expiration date and pouch integrity before opening. Record the lot number, insertion date, arm and exact site in the chart, confirm palpability with the patient at the end of the visit, and issue the user card. Set the removal reminder at insertion rather than later.
On sourcing, Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013; the contraceptive product listings and the Nexplanon brand listing are organized for practice purchasing teams. Wider inventory and recordkeeping habits are covered in our clinic operations articles.
A Short Clinic Checklist
- Before insertion: exclude pregnancy, review contraindications and enzyme-inducing drugs.
- During consent: name bleeding unpredictability first, then common systemic effects.
- At the visit’s end: palpate with the patient, document site, lot and arm, issue the user card.
- At follow-up: ask about bleeding burden, mood and headache before asking about satisfaction.
- For new symptoms late in the term: investigate rather than attribute.
- If not palpable: advise backup contraception, image, and refer for specialist removal.
- At removal: confirm the retrieved implant is intact and arrange ongoing contraception the same day.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
